Skip to main content

Michel Georges Khouri

Associate Professor of Medicine
Medicine, Cardiology
Duke South Clinic, Box 3254 DUMC, Durham, NC 27710

Selected Grants


ConTTRibute

Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2022 - 2032

CardioTTRansform-OLE

Clinical TrialPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2023 - 2028

Machine Learning Guided Precision Genetic Testing for Identification of Monogenic Cardiovascular Disorders

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028

Attribute OLE

Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2022 - 2027

ANNAMYCIN III - Acute Myeloid Leukemia

Clinical TrialPrincipal Investigator · Awarded by Moleculin Biotech, Inc. · 2022 - 2025

ConTTRibute

Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2022 - 2032

CardioTTRansform-OLE

Clinical TrialPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2023 - 2028

Machine Learning Guided Precision Genetic Testing for Identification of Monogenic Cardiovascular Disorders

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028

Attribute OLE

Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2022 - 2027

ANNAMYCIN III - Acute Myeloid Leukemia

Clinical TrialPrincipal Investigator · Awarded by Moleculin Biotech, Inc. · 2022 - 2025

Strategy to Improve Patient Outcomes by Silencing TTR Formation in ATTR-CM

Clinical TrialPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2020 - 2024

MB-107 Annamycin II Sarcoma

Clinical TrialPrincipal Investigator · Awarded by Moleculin Biotech, Inc. · 2021 - 2024

The Cardiac Amloidosis Registry Study

ResearchPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2021 - 2023

CHEPRI: Chronology of Effects of Patisiran on Cardiac Amyloidosis

Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2021 - 2023

Cardiac Amyloid: The Duke Experience

ConferencePrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2022 - 2022

AG10-301 ATTRIBUTE

Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2019 - 2022

AG10 ATTR-CM R6MWT

Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2021 - 2022

Attract Extension-- Endeavor Extension Study

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2021

ISCHEMIA: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches

Clinical TrialPrincipal Investigator · Awarded by New York University School of Medicine · 2014 - 2020

EXCITE

ResearchPrincipal Investigator · Awarded by Sloan Kettering Institute · 2018 - 2019

Educational Preceptorship Program

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Pfizer, Inc. · 2019 - 2019

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches

Clinical TrialPrincipal Investigator · Awarded by New York University School of Medicine · 2014 - 2018

SCUSF 0806 Phase II placebo--controlled trial of lisinopril and Coreg

ResearchCo Investigator · Awarded by University of South Florida · 2013 - 2014

External Relationships


  • Alnylam Pharmaceutical, Inc.
  • Chimerix, Inc.
  • Eidos Therapeutics/BridgeBio
  • HOPO Therapeutics
  • IONIS-AstraZeneca Pharmaceuticals
  • Alnylam Pharmaceutical, Inc.
  • Chimerix, Inc.
  • Eidos Therapeutics/BridgeBio
  • HOPO Therapeutics
  • IONIS-AstraZeneca Pharmaceuticals
  • Moleculin Biotech Inc.
  • PRIME Education, LLC
  • Pfizer Inc.
  • SpringWorks Therapeutics

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.